Drug Profile
ASP 6858
Alternative Names: ASP6858Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Renal failure
Most Recent Events
- 11 May 2016 Discontinued - Phase-I for Renal failure (In volunteers) in United Kingdom (PO)
- 06 Oct 2015 Astellas Pharma restarts enrolment in a phase I trial in Healthy volunteers in United Kingdom (NCT02359032)
- 06 Aug 2015 Astellas Pharma suspends a phase I trial in Healthy volunteers in United Kingdom due to operational reasons (PO) (NCT02359032)